Lassa fever: Symptoms of Ebola-like virus as first UK death confirmed

Three cases of acute viral haemorrhagic illness have been reported in the UK

<p>Lassa fever is among a US list of ‘category A’ diseases, deemed to have the potential for major public health impact, alongside anthrax and botulism</p>

Lassa fever is among a US list of ‘category A’ diseases, deemed to have the potential for major public health impact, alongside anthrax and botulism

Leer en Español

The death of a patient in the UK suffering from Lassa fever has heightened concern around the illness after a third case was reported.

The UK Health Security Agency (UKHSA) said it was contacting individuals who had been in close contact with the infected patients after the death was confirmed last week.

Commenting on the recent cases detected in the UK, which were linked to travel to west Africa, Dr Susan Hopkins, chief medical advisor at UKHSA, said: “Cases of Lassa fever are rare in the UK and it does not spread easily between people.

“The overall risk to the public is very low.

“UKHSA and the NHS have well established and robust infection control procedures for dealing with cases of imported infectious disease and these will be reinforced.”

Lassa fever is described as an acute viral haemorrhagic illness caused by the Lassa virus, and people tend to become infected through exposure to food or other items contaminated with infected rat urine or faeces.

The disease, which is endemic in a number of West African countries, can also be spread through infected bodily fluids.

On Monday, Nigerian media reported the latest outbreak in that country had claimed 48 lives already this year, with those in their 20s said to be the predominant age group affected.

Microbiologist explains origins of Lassa Fever

According to the World Health Organisation (WHO), the incubation period of Lassa fever ranges from six to 21 days, with the onset of the disease usually developing gradually.

Typical symptoms include a fever, general weakness, headache, sore throat, muscle pain, chest pain, nausea, vomiting, diarrhoea, cough, and abdominal pain, the WHO said.

Facial swelling, fluid in the lung cavity, bleeding from bodily orifices and low blood pressure may also develop in the most severe cases.

This can be followed by shock, seizures, a tremor, disorientation, and coma, and hearing loss occurs in about one in four patients who survive the disease.

The WHO said that in around half of these cases, partial hearing returns over the course of one to three months.

Nigeria is battling another outbreak of Lassa fever

The disease is especially severe late in pregnancy, and death among patients generally tends to occur within two weeks of onset.

Lassa fever initially presents in a similar way to malaria or ebola, making it more difficult to distinguish early on.

Named after the Nigerian town where it was first identified in 1969, Lassa fever is among a US list of ‘category A’ diseases, deemed to have the potential for major public health impact, alongside anthrax and botulism.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in